CN108424449A - 针对艰难梭菌的主要外毒素TcdA和TcdB的中和抗体 - Google Patents

针对艰难梭菌的主要外毒素TcdA和TcdB的中和抗体 Download PDF

Info

Publication number
CN108424449A
CN108424449A CN201810242539.6A CN201810242539A CN108424449A CN 108424449 A CN108424449 A CN 108424449A CN 201810242539 A CN201810242539 A CN 201810242539A CN 108424449 A CN108424449 A CN 108424449A
Authority
CN
China
Prior art keywords
antibody
ser
seq
gly
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810242539.6A
Other languages
English (en)
Chinese (zh)
Inventor
D·P·哈姆费雷斯
D·J·莱特伍德
K·L·泰森
D·E·O·奈特
K·J·M·赫伍
J·E·康普森
M·J·T·裴知
A·C·佩内
N·L·菲舍
B·麦肯泽
M·寇克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46881094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN108424449(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UCB SA filed Critical UCB SA
Publication of CN108424449A publication Critical patent/CN108424449A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91091—Glycosyltransferases (2.4)
    • G01N2333/91097—Hexosyltransferases (general) (2.4.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201810242539.6A 2011-09-16 2012-09-10 针对艰难梭菌的主要外毒素TcdA和TcdB的中和抗体 Pending CN108424449A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161535532P 2011-09-16 2011-09-16
US61/535,532 2011-09-16
US201261638731P 2012-04-26 2012-04-26
US61/638,731 2012-04-26
CN201280049537.6A CN103958544B (zh) 2011-09-16 2012-09-10 针对艰难梭菌的主要外毒素TcdA和TcdB的中和抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280049537.6A Division CN103958544B (zh) 2011-09-16 2012-09-10 针对艰难梭菌的主要外毒素TcdA和TcdB的中和抗体

Publications (1)

Publication Number Publication Date
CN108424449A true CN108424449A (zh) 2018-08-21

Family

ID=46881094

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810242539.6A Pending CN108424449A (zh) 2011-09-16 2012-09-10 针对艰难梭菌的主要外毒素TcdA和TcdB的中和抗体
CN201280049537.6A Expired - Fee Related CN103958544B (zh) 2011-09-16 2012-09-10 针对艰难梭菌的主要外毒素TcdA和TcdB的中和抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280049537.6A Expired - Fee Related CN103958544B (zh) 2011-09-16 2012-09-10 针对艰难梭菌的主要外毒素TcdA和TcdB的中和抗体

Country Status (30)

Country Link
US (2) US10752676B2 (enExample)
EP (2) EP3617227A3 (enExample)
JP (3) JP6152107B2 (enExample)
KR (1) KR20140063825A (enExample)
CN (2) CN108424449A (enExample)
AU (1) AU2012307157B2 (enExample)
BR (1) BR112014006175B1 (enExample)
CA (1) CA2848611A1 (enExample)
CL (1) CL2014000491A1 (enExample)
CO (1) CO6930310A2 (enExample)
CY (1) CY1121673T1 (enExample)
DK (1) DK2758432T3 (enExample)
EA (1) EA032475B1 (enExample)
EC (1) ECSP14013316A (enExample)
ES (1) ES2729278T3 (enExample)
HK (1) HK1199463A1 (enExample)
HR (1) HRP20190917T1 (enExample)
HU (1) HUE043661T2 (enExample)
IL (1) IL231167A0 (enExample)
LT (1) LT2758432T (enExample)
MX (1) MX2014002769A (enExample)
PE (1) PE20141547A1 (enExample)
PH (1) PH12014500456A1 (enExample)
PL (1) PL2758432T3 (enExample)
PT (1) PT2758432T (enExample)
SG (2) SG10201701055WA (enExample)
SI (1) SI2758432T1 (enExample)
TN (1) TN2014000101A1 (enExample)
WO (1) WO2013038156A1 (enExample)
ZA (1) ZA201402760B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110607314A (zh) * 2019-10-31 2019-12-24 四川农业大学 一种TcdB RBD基因、重组RBD蛋白和应用
CN111763263A (zh) * 2020-07-09 2020-10-13 宁夏医科大学 一种艰难梭菌抗原及多克隆抗体的制备方法和检测试剂盒
CN112500484A (zh) * 2021-01-29 2021-03-16 迈杰转化医学研究(苏州)有限公司 一种抗trop2抗体及其应用

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10752676B2 (en) * 2011-09-16 2020-08-25 Ucb Biopharma Sprl Neutralising antibodies to the major exotoxins TCDA and TCDB of Clostridium difficile
WO2014085749A2 (en) * 2012-11-28 2014-06-05 Cnj Holdings, Inc. Antibodies against clostridium difficile
WO2014176276A1 (en) * 2013-04-22 2014-10-30 Board Of Regents Of The University Of Oklahoma Clostridium difficile vaccine and methods of use
WO2015123767A1 (en) * 2014-02-18 2015-08-27 The Hospital For Sick Children Compositions and methods for treating or preventing clostridium infection
US9717711B2 (en) 2014-06-16 2017-08-01 The Lauridsen Group Methods and compositions for treating Clostridium difficile associated disease
WO2016178773A1 (en) * 2015-04-06 2016-11-10 Saureus, Inc. System and method for detecting clostridium difficile toxins
HK1246196A1 (zh) * 2015-04-15 2018-09-07 Medimmune, Llc 用於治疗艰难梭菌(clostridium difficile)感染和相关疾病的方法
PE20221007A1 (es) 2015-06-24 2022-06-15 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad disenada
EP3344276B1 (en) 2015-09-03 2020-04-22 The Board of Regents of the University of Oklahoma Peptide inhibitors of clostridium difficile tcdb toxin
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
WO2017055542A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
USD864160S1 (en) 2016-12-06 2019-10-22 Samsung Electronics Co., Ltd. Audio device
RU2761249C2 (ru) * 2016-12-14 2021-12-06 Мерк Шарп энд Доум Корп. Человеческие генетические маркеры, ассоциированные с ответом на средства для лечения, которые целенаправленно воздействуют на токсин b clostridium difficile

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101014620A (zh) * 2004-02-06 2007-08-08 马萨诸塞州大学 抗艰难梭菌毒素抗体及其用途
CN101500581A (zh) * 2006-06-08 2009-08-05 科内尔研究基金会 编码艰难梭菌毒素a和毒素b受体结合域的密码子优化dna分子及其使用方法
WO2009108652A1 (en) * 2008-02-28 2009-09-03 3M Innovative Properties Company Antibodies to clostridium difficile spores and uses thereof
WO2010094970A1 (en) * 2009-02-20 2010-08-26 Health Protection Agency Antibodies to clostridium difficile toxins

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
ZA929870B (en) 1991-12-23 1993-08-18 Duphar Int Res Adjuvants
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
EP0689454B2 (en) 1993-03-23 2005-02-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
ES2149340T3 (es) 1993-11-17 2000-11-01 Om Pharma Disacaridos de glucosamina, metodo para su preparacion, composicion farmaceutica que los comprende, y su uso.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
DE69535905D1 (de) 1994-07-15 2009-02-26 Coley Pharm Group Inc Immunomodulatorische Oligonukleotide
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
EP0930893B1 (en) 1996-10-11 2005-04-13 The Regents of The University of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
WO1999010008A1 (en) 1997-08-29 1999-03-04 Aquila Biopharmaceuticals, Inc. Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
US7226597B2 (en) * 2002-06-17 2007-06-05 The Board Of Regents Of The University Of Oklahoma Mutants of Clostridium difficile toxin B and methods of use
BR0215954A (pt) * 2002-11-26 2005-09-13 Uc Tech Métodos de redução da possibilidade de mortalidade em um animal, de expressão virulenta em um patógeno intestinal, e da expressão de adesina / lectina pa-i em uma célula bacteriana, de inibição de expressão de adesina / lectina pa-i em um patógeno intestinal, de ativação induzida por intestino de adesina / lectina pa-i, de mudança morfológica induzida por c4-hsl de um patógeno intestinal, e de aderência de célula bacteriana em um intestino de mamìfero, de melhoria de patogênese intestinal, de prevenção de uma doença ou condição anormal, de infecção de pele e respiratória, de uma doença sexualmente transmitida, de um distúrbio de trato digestivo, de perda de capacidade lactante em um animal, e de desenvolvimento de um distúrbio epitelial mediado por micróbio em uma animal de idade de amamentação, de irrigação de pelo menos uma porção do trato urinário, e para monitoração da administração de poli (etileno-glicol) (peg) a um animal, composição farmacêutica, kits para a prevenção ou tratamento terapêutico de sepsia derivada de intestino, e para a monitoração da administração de poli (etileno-glicol), e, preservativo
JP4603894B2 (ja) 2002-12-03 2010-12-22 ユセベ ファルマ ソシエテ アノニム 抗体産生細胞を同定するためのアッセイ
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
AU2004253738A1 (en) 2003-07-01 2005-01-13 Ucb Pharma S.A. Modified antibody Fab fragments
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
BRPI0517592B1 (pt) 2004-12-27 2016-03-15 Huntsman Corp Australia Pty Ltd formulação agroquímica sólida, método para preparar a mesma, e, formulação de concentração de suspensão
US20090087478A1 (en) 2004-12-27 2009-04-02 Progenics Pharmaceuticals (Nevada), Inc. Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
JP5592792B2 (ja) * 2007-09-26 2014-09-17 ユセベ ファルマ ソシエテ アノニム 二重特異性抗体の融合体
HUE032894T2 (hu) * 2008-06-25 2017-11-28 Esbatech Alcon Biomed Res Unit VEGF-gátló, stabilis és oldható antitestek
LT2334705T (lt) 2008-09-26 2017-03-27 Ucb Biopharma Sprl Biologiniai produktai
MX339253B (es) * 2010-04-15 2016-05-18 Progenics Pharm Inc Anticuerpos para el tratamiento de infeccion y enfermedad asociadas con clostridium dificile.
US9771416B2 (en) * 2010-10-25 2017-09-26 National Research Council Of Canada Clostridium difficile-specific antibodies and uses thereof
US9815889B2 (en) * 2011-08-02 2017-11-14 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Antibodies for prevention and treatment of diseases caused by clostridium difficile
US10752676B2 (en) * 2011-09-16 2020-08-25 Ucb Biopharma Sprl Neutralising antibodies to the major exotoxins TCDA and TCDB of Clostridium difficile
UA112203C2 (uk) * 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
EP2921502A4 (en) * 2012-10-19 2016-09-28 Evec Inc AGAINST TOXIN FROM CLOSTRIDIUM DIFFICILE OR ANTIGENBINDING FRAGMENT SPECIFIC HUMAN ANTIBODY
GB201411320D0 (en) * 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201411420D0 (en) * 2014-06-26 2014-08-13 Ucb Biopharma Sprl Antibody constructs
US9815886B2 (en) * 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101014620A (zh) * 2004-02-06 2007-08-08 马萨诸塞州大学 抗艰难梭菌毒素抗体及其用途
CN101500581A (zh) * 2006-06-08 2009-08-05 科内尔研究基金会 编码艰难梭菌毒素a和毒素b受体结合域的密码子优化dna分子及其使用方法
WO2009108652A1 (en) * 2008-02-28 2009-09-03 3M Innovative Properties Company Antibodies to clostridium difficile spores and uses thereof
CN101980723A (zh) * 2008-02-28 2011-02-23 3M创新有限公司 艰难梭菌芽孢的抗体及其用途
WO2010094970A1 (en) * 2009-02-20 2010-08-26 Health Protection Agency Antibodies to clostridium difficile toxins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BABCOCK GREGORY J等: "Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters.", 《INFECTION AND IMMUNITY,AMERICAN SOCIETY FOR MACROBIOLOGY》 *
HUSSACK GREG等: "Toxin-specific antibodies for the treatment of clostridium difficile:current status and future perspectives.", 《TOXINS》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110607314A (zh) * 2019-10-31 2019-12-24 四川农业大学 一种TcdB RBD基因、重组RBD蛋白和应用
CN110607314B (zh) * 2019-10-31 2022-09-23 四川农业大学 一种TcdB RBD基因、重组RBD蛋白和应用
CN111763263A (zh) * 2020-07-09 2020-10-13 宁夏医科大学 一种艰难梭菌抗原及多克隆抗体的制备方法和检测试剂盒
CN112500484A (zh) * 2021-01-29 2021-03-16 迈杰转化医学研究(苏州)有限公司 一种抗trop2抗体及其应用
CN112500484B (zh) * 2021-01-29 2021-06-08 迈杰转化医学研究(苏州)有限公司 一种抗trop2抗体及其应用

Also Published As

Publication number Publication date
AU2012307157A1 (en) 2014-04-24
AU2012307157B2 (en) 2017-08-03
JP2015501286A (ja) 2015-01-15
EP3617227A2 (en) 2020-03-04
BR112014006175B1 (pt) 2020-02-11
ECSP14013316A (es) 2014-08-29
JP6603685B2 (ja) 2019-11-06
EP2758432B1 (en) 2019-03-06
CN103958544B (zh) 2018-04-24
ZA201402760B (en) 2016-03-30
SG10201701055WA (en) 2017-03-30
MX2014002769A (es) 2014-06-11
HK1199463A1 (en) 2015-07-03
BR112014006175A2 (pt) 2017-04-04
EP3617227A3 (en) 2020-06-03
US20140348844A1 (en) 2014-11-27
EP2758432A1 (en) 2014-07-30
US10752676B2 (en) 2020-08-25
US20200377578A1 (en) 2020-12-03
HUE043661T2 (hu) 2019-08-28
TN2014000101A1 (en) 2015-07-01
IL231167A0 (en) 2014-04-30
KR20140063825A (ko) 2014-05-27
PL2758432T3 (pl) 2019-08-30
EA201400345A1 (ru) 2014-09-30
PE20141547A1 (es) 2014-10-25
CN103958544A (zh) 2014-07-30
ES2729278T3 (es) 2019-10-31
PT2758432T (pt) 2019-06-14
JP6152107B2 (ja) 2017-06-21
JP2017149773A (ja) 2017-08-31
EA032475B1 (ru) 2019-06-28
WO2013038156A1 (en) 2013-03-21
HRP20190917T1 (hr) 2019-07-26
DK2758432T3 (da) 2019-06-03
CL2014000491A1 (es) 2014-12-26
SG11201400193SA (en) 2014-05-29
CA2848611A1 (en) 2013-03-21
NZ623293A (en) 2016-05-27
CY1121673T1 (el) 2020-07-31
PH12014500456A1 (en) 2014-04-14
CO6930310A2 (es) 2014-04-28
JP2020037555A (ja) 2020-03-12
SI2758432T1 (sl) 2019-07-31
LT2758432T (lt) 2019-06-10

Similar Documents

Publication Publication Date Title
CN103958544B (zh) 针对艰难梭菌的主要外毒素TcdA和TcdB的中和抗体
JP6159854B2 (ja) クロストリジウム・ディフィシル関連感染症および疾患を治療するための抗体
US20190330321A1 (en) Antagonist antibodies that bind to human tgfb1, tgfb2 and to tgfb3 and their use for the treatment of lung fibrosis
WO2016073853A1 (en) Anti-pro/latent-myostatin antibodies and uses thereof
WO2017049011A1 (en) Anti-pro/latent-myostatin antibodies and uses thereof
CN105121466A (zh) 靶向m-csf的抗体
US20240301073A1 (en) LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb1 AND USES THEREOF
NZ623293B2 (en) Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
EA046745B1 (ru) Способ лечения рака активируемым антителом против pdl1
HK1179982B (en) Antibodies for the treatment of clostridium difficile-associated infection and disease
HK1179982A (en) Antibodies for the treatment of clostridium difficile-associated infection and disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180821

WD01 Invention patent application deemed withdrawn after publication